14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $18.05 $25.50 Thursday, 2nd May 2024 PHVS stock ended at $23.53. This is 4.23% less than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 8.56% from a day low at $23.49 to a day high of $25.50.
90 days $18.05 $33.00
52 weeks $7.93 $33.00

Historical Pharvaris B.V. prices

Date Open High Low Close Volume
Jan 16, 2024 $28.30 $28.30 $27.67 $27.85 26 055
Jan 12, 2024 $26.30 $28.37 $25.25 $28.28 47 706
Jan 11, 2024 $25.51 $26.50 $25.27 $26.25 38 039
Jan 10, 2024 $25.44 $26.58 $24.52 $26.10 50 475
Jan 09, 2024 $25.41 $25.70 $24.84 $25.64 63 175
Jan 08, 2024 $25.01 $26.24 $24.59 $26.01 56 212
Jan 05, 2024 $25.11 $25.94 $25.00 $25.00 20 050
Jan 04, 2024 $25.22 $25.52 $25.02 $25.32 5 302
Jan 03, 2024 $25.18 $26.64 $24.97 $25.27 58 693
Jan 02, 2024 $28.00 $28.00 $24.93 $25.87 88 312
Dec 29, 2023 $27.88 $28.88 $27.61 $28.05 173 733
Dec 28, 2023 $27.10 $28.08 $26.54 $27.94 159 270
Dec 27, 2023 $26.25 $27.50 $26.06 $27.23 29 763
Dec 26, 2023 $26.80 $27.33 $25.56 $26.25 25 435
Dec 22, 2023 $27.11 $27.50 $26.61 $26.92 138 626
Dec 21, 2023 $26.61 $27.50 $25.94 $27.00 72 866
Dec 20, 2023 $26.50 $27.30 $26.09 $26.51 218 153
Dec 19, 2023 $26.69 $27.71 $26.02 $26.73 275 800
Dec 18, 2023 $25.55 $26.88 $25.00 $26.27 153 734
Dec 15, 2023 $25.84 $28.00 $25.01 $25.97 181 778
Dec 14, 2023 $25.92 $26.21 $25.00 $25.84 281 182
Dec 13, 2023 $25.50 $25.91 $25.00 $25.85 235 418
Dec 12, 2023 $25.90 $26.98 $24.70 $25.50 336 059
Dec 11, 2023 $26.68 $26.68 $25.13 $26.28 139 536
Dec 08, 2023 $25.42 $25.99 $24.49 $25.42 243 712
Click to get the best stock tips daily for free!

About Pharvaris B.V.

Pharvaris B.V. Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical ... PHVS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT